Receptor News and Research

RSS

Molecular features of SARS-CoV-2 variant receptor binding

Researchers have been investigating the changes in receptor binding in these variants that increase the danger they pose.

25 Oct 2021

Role of SARS-CoV-2 infection biomarkers in HIV replication

A new study investigates the role of the S100A8/A9 complex in the replication of HIV.

25 Oct 2021

Blood pressure drug increases SARS-CoV-2 receptors in transmission and pathogenesis associated tissues

A new study aimed to determine whether ACE2 targeting drugs change the tissue levels of ACE2 in healthy mice.

25 Oct 2021

Study suggests seropositive individuals produce anti-SARS-CoV-2 antibodies with improved potency and breadth

Researchers isolated single cells among individuals with and without prior infection with the SARS-CoV-2 vaccinated with BNT162b2 mRNA vaccine and compared the nature of the neutralizing antibody response against the original Wuhan virus and the subsequent variants.

25 Oct 2021

Men with Stage IV breast cancer who are receptive to systemic therapy benefit from surgery

Men with Stage IV breast cancer and known estrogen (ER) and progesterone receptor (PR) status benefit from surgical intervention and from trimodal therapy (systemic therapy, surgery, and radiation), according to a study presented at the virtual American College of Surgeons (ACS) Clinical Congress 2021.

25 Oct 2021

Study discloses molecular mechanism of oligodendrocyte myelination by osteocalcin in the CNS

Osteocalcin (OCN) is a multifunctional bone-derived hormone that modulates numerous physiological activities. OCN can cross the blood brain barrier (BBB) and thus play critical roles in neuronal and brain development.

25 Oct 2021

Targeting SARS-CoV-2 with Chaga mushroom – a natural antiviral compound

A new study examines the potential binding interaction of the beneficial components of Chaga mushroom with that of the SARS-CoV-2 RBD.

24 Oct 2021

A comparison between Pfizer/BioNTech's and Sinopharm's SARS-CoV-2 vaccines

Researchers compare antibody titers elicited the Pfizer‐BioNTech mRNA and the classic inactivated virus Sinopharm vaccines.

24 Oct 2021

Immune evasion by SARS-CoV-2 facilitated by a mutational hotspot in the NTD

Researchers discuss mutations in the NTD of the spike protein, which contains an antigenic “supersite” and is the target for nAbs.

24 Oct 2021

New method for safe engineering of therapeutic cells with photothermal nanofibers

Professor Braeckmans from Ghent University focused the last ten years on a method for safe engineering of therapeutic cells with photothermal nanofibers.

22 Oct 2021

Mu and C.1.2 variant spike proteins partially resistant to neutralization by vaccine-elicited antibodies

A team of researchers measured the infectivity of SARS-CoV-2 variants C.1.2, Mu, and Delta+501S spike proteins and determined the susceptibility to neutralizing antibodies.

22 Oct 2021

Study shows immune profile heterogeneity amongst healthy adults

Researchers opted to use single-cell RNA-seq to observe single cells in detail as they encounter a specific antigen.

22 Oct 2021

Replication of SARS-CoV-2 variants in different cell and organ models

In this study, the replication of B.1.1.7 viruses was analyzed in different cell and organ models and dwarf hamsters.

22 Oct 2021

Development of a safe and effective COVID-19 nanoparticle vaccine

Researchers from ReVacc scientific have attempted to demonstrate the effectiveness of a new vaccine, REVC-128, two weeks post-administration.

22 Oct 2021

Hydrogel-based vaccine delivery system evokes antibody response against SARS-CoV-2

Researchers from Stanford University have been attempting to create a hydrogel-based vaccine delivery system that could improve the immune response's strength and duration.

22 Oct 2021

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

Amidst growing concerns on the use and potential benefits of convalescent plasma therapy, a research group in the United States has identified three human antibodies (Abs) that, when combined, demonstrate both robust viral suppressive properties against all tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Variants of Concern (VoC) in vitro and profound antiviral efficacy in vivo.

22 Oct 2021

Novel Einstein-developed strategy successfully suppresses HIV infections in mice

Armed with a novel strategy they developed for bolstering the body's immune response, scientists at Albert Einstein College of Medicine have successfully suppressed HIV infections in mice - offering a path to a functional cure for HIV and other chronic viral infections.

21 Oct 2021

CAR-T cell treatment's efficacy in hematological malignancies predicted by epigenetics

One in five cancers affects blood cells and lymph nodes, causing leukemias and lymphomas, respectively. Although their treatment with drugs has led to a great advance in their cure, there are cases where there is no clinical response or resistance to them is generated.

21 Oct 2021

Development of a plant-based platform for the production of SARS-CoV-2 antigen

Scientists have recently focused on the development of plant-based recombinant protein platforms.

21 Oct 2021

Broadly protective vaccines against coronaviruses needed to protect against future outbreaks

The coronavirus disease 2019 (COVID-19) pandemic, caused by the β-coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), alerted the world to the seriousness of the threat posed by novel viruses.

20 Oct 2021

Receptor News and Research

Molecular features of SARS-CoV-2 variant receptor binding

Role of SARS-CoV-2 infection biomarkers in HIV replication

Blood pressure drug increases SARS-CoV-2 receptors in transmission and pathogenesis associated tissues

Study suggests seropositive individuals produce anti-SARS-CoV-2 antibodies with improved potency and breadth

Men with Stage IV breast cancer who are receptive to systemic therapy benefit from surgery

Study discloses molecular mechanism of oligodendrocyte myelination by osteocalcin in the CNS

Targeting SARS-CoV-2 with Chaga mushroom – a natural antiviral compound

A comparison between Pfizer/BioNTech's and Sinopharm's SARS-CoV-2 vaccines

Immune evasion by SARS-CoV-2 facilitated by a mutational hotspot in the NTD

New method for safe engineering of therapeutic cells with photothermal nanofibers

Mu and C.1.2 variant spike proteins partially resistant to neutralization by vaccine-elicited antibodies

Study shows immune profile heterogeneity amongst healthy adults

Replication of SARS-CoV-2 variants in different cell and organ models

Development of a safe and effective COVID-19 nanoparticle vaccine

Hydrogel-based vaccine delivery system evokes antibody response against SARS-CoV-2

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

Novel Einstein-developed strategy successfully suppresses HIV infections in mice

CAR-T cell treatment's efficacy in hematological malignancies predicted by epigenetics

Development of a plant-based platform for the production of SARS-CoV-2 antigen

Broadly protective vaccines against coronaviruses needed to protect against future outbreaks

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News